Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 12, 2019

View Archived Issues

Getting ncAAs ready for playoffs

LRG as a novel biomarker to monitor the efficacy of adalimumab treatment in UC and CD

Long, low growth factor signaling promotes healing

Glutamine blockade: Bad for tumor cells, good for T cells

Cerecor announces milestones in clinical development programs of CERC-301 and CERC-802

FDA clears IND application for ACH-5228

Indalo Therapeutics presents first clinical data for IDL-2965

Topline phase II data presented for TNP-2092

Turning Point Therapeutics initiates phase I/II trial of TPX-0046

SAR-20351 demonstrates promising safety and efficacy in syngeneic tumor models

MRX-1669, a novel small-molecule Myc inhibitor with promising in vitro activity

ALBI as a promising prognostic marker in predicting survival from HCC

HOOKIPA Pharma presents phase I data for CMV vaccine HB-101

Emergex Vaccines descibes new filovirus vaccines

Seres Therapeutics discloses bacterial compositions

Dopamine D1 receptor positive allosteric modulators discovered at Lilly

Baylor College of Medicine, Tvardi Therapeutics patent STAT3 inhibitors

Medshine Discovery identifies new LRRK2 inhibitors

Phase IIa data for multiple doses of GSK-3389404 in chronic HBV on stable nucleos(t)ide therapy

IL-7- and/or IL-12-expressing oncolytic viruses enhance antitumor immune responses in mice

New immunotherapy delivering previously encountered antigenic peptides leads to anticancer response

New anti-CD147 antibodies induce SMAD and JNK signaling and tumor shrinkage in xenograft models

New technology improves prediction of liver toxicity

Phase III portion of CARDINAL study of bardoxolone in Alport syndrome meets primary endpoint

European Commission grants conditional marketing authorization to Ebola Zaire vaccine Ervebo

Otsuka and Avanir decide to continue development of AVP-786 for agitation in Alzheimer's dementia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...